Its an exciting time to be in cancer diagnostics – Chris Abbosh
Thank you American Society of Clinical Oncology (ASCO) and the ASCO Breakthrough 2023 organizers for an 💡 insightful meeting in Yokohama covering the latest breakthroughs in cancer research.
At yesterdays Keynote I shared Cancer Research UK (CRUK) TRACERx research in the field of minimal residual disease (ctDNA) in lung cancer and the emerging role it can play in identifying patients with micro-metastatic disease who require adjuvant treatment escalation.
Next-generation transformative technologies are allowing us to detect relapsing disease, which allows us to determine the most appropriate treatment options for individual patients which in turn can optimize patient outcomes. Its an exciting time to be in cancer diagnostics!
ASCO Daily covered the TRACERx MRD, ASCO Breakthrough 2023 keynote here: https://lnkd.in/eTwBWM6p
For more info on liquid biopsy and ctDNA: Click here